Medscape4h
Two-Drug HIV Regimen Matches Standard of Care Therapy in Absence of Drug Resistance Testing
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
HIV Drugs Market Poised For Significant Growth, Expected To Reach $36,495.47 Million By 2027 CAGR 3.8%
North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...